Skip to main content

Table 1 Baseline characteristics of the total participants

From: Effectiveness of mechanical thrombectomy in cancer-related stroke and associated factors with unfavorable outcome

  Cancer-related stroke Control p value
n (%) or mean ± SD or median (IQR) n (%) or mean ± SD or median (IQR)
Total 34 (100%) 307 (100%)  
Age, years 64.5 ± 11.4 68.9 ± 14.0 0.124
Sex, male [n (%)] 17 (50%) 161 (52.4%) 0.921
Premorbid mRS score 0 (0–1.75) 0 (0–0) 0.294
Baseline NIHSS score 18 (11–23) 15 (8–19) 0.290
Comorbidities
 Hypertension 22 (64.7%) 219 (71.3%) 0.768
 Diabetes 14 (41.1%) 106 (34.5%) 0.621
 Hyperlipidemia 9 (26.5%) 139 (45.3%) 0.328
 Coronary artery disease 5 (14.7%) 59 (19.2%) 0.142
 Prior stroke or TIA 6 (17.7%) 82 (26.7%) 0.306
 Smoking 5 (14.7%) 92 (30.0%) 0.072
 Atrial fibrillation 0 (0%) 175 (57.0%) < 0.001
Previous use of antithrombotics† 13 (38.2%) 98 (31.9%) 0.336
Laboratory findings
 Hemoglobin, g/dℓ 10.8 ± 2.1 13.1 ± 2.1 < 0.001
 White blood cells, 103/μL 10.7 ± 6.3 8.8 ± 3.5 0.042
 Platelet counts, 103/μL 187.7 ± 105.9 216.3 ± 72.3 < 0.001
 Prothrombin time, sec/INR 1.2 ± 0.2 1.1 ± 0.3 0.562
 Total cholesterol, mg/dℓ 150.2 ± 47 160.2 ± 42.3 0.134
 Triglyceride, mg/dℓ 110.4 ± 52.7 99.0 ± 53.5 0.172
 HDL cholesterol, mg/dℓ 38.1 ± 17 47.2 ± 15.1 0.094
 LDL cholesterol, mg/dℓ 92.1 ± 32 97.5 ± 37.5 0.328
 C-reactive protein, mg/dℓ 6.3 ± 8.2 1.5 ± 3.5 < 0.001
In-hospital Stroke 11 (32.4%) 24 (7.8%) < 0.001
Occlusion site
 Middle cerebral artery 24 (70.6%) 172 (56.0%) 0.143
  M1 18 (52.9%) 118 (38.4%) 0.139
  M2 6 (17.6%) 54 (17.6%) 0.993
 Anterior cerebral artery 1 (2.9%) 16 (5.2%) 0.478
 Posterior cerebral artery/Basilar artery 4 (11.8%) 54 (17.6%) 0.479
 Internal carotid artery 5 (14.7%) 63 (20.5%) 0.504
 Common carotid artery 0 (0%) 2 (0.6%) 0.998
Use of intravenous rtPA 9 (26.5%) 80 (26.1%) 0.959
  1. Abbreviations: SD standard deviation, IQR interquartile range, mRS modified Rankin scale, NIHSS National institute of health stroke scale, TIA transient ischemic attack, INR international normalized ratio, HDL High-density lipoprotein, LDL low-density lipoprotein, rtPA recombinant tissue plasminogen activator
  2. †Antiplatelets and anticoagulation agents